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Abstract
Background: Second primary tumors (SPTs) are a common cause of reduced
life expectancy in patients treated for head and neck cancer (HNC). This phe-
nomenon forms an area to be addressed during posttreatment follow-up.
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Received: 21 August 2019 Revised: 22 October 2019 Accepted: 6 November 2019
DOI: 10.1002/hed.26016
456 © 2019 Wiley Periodicals, Inc. Head & Neck. 2020;42:456–466.wileyonlinelibrary.com/journal/hed
Methods: We conducted a systematic review of literature following PRISMA
guidelines, from 1979 to 2019, to investigate incidence of SPTs, synchronous,
and metachronous, in HNC population.
Results: Our review includes data of 456 130 patients from 61 articles. With a
minimum follow-up of 22 months, mean incidence of SPTs was 13.2% (95% CI:
11.56-14.84): 5.3% (95% CI: 4.24-6.36) for synchronous SPTs and 9.4% (95% CI:
7.9-10.9) for metachronous SPTs. The most frequent site for SPTs was head and
neck area, followed by the lungs and esophagus.
Conclusion: Although with wide variations between studies, the rate of SPTs
in HNC patients is high. Given the impact in the prognosis, we must develop
strategies for the early diagnosis of SPTs.
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1 | INTRODUCTION
Head and neck cancers (HNCs) are the sixth most com-
mon malignancy worldwide. Approximately two thirds
of HNC patients present with locally advanced disease.1
The survival rates for early stage disease are high, but
despite advances in treatment options, about 40% of
locally advanced cases will recur after front-line treat-
ment. More than 50% of these patients will develop a
loco-regional recurrence within 2 years, and a 20% to
30% of those patients will develop distant metastases.2
In contrast, most HNC patients are tobacco and alcohol
consumers who have a significant risk of second pri-
mary tumors (SPTs), which may be detected either at
the point of diagnosis or during follow-up.3 SPTs are a
major cause of mortality in HNC survivors.4-6 It is pos-
tulated that this phenomenon is the result of “field can-
cerization” which denotes the entire aerodigestive
epithelium having been exposed to chronic carcinogenic
insults and is therefore predisposed to develop multiple
premalignant and malignant lesions.7 The SPT risk is
about 2% to 4% per year, a rate of about 10% to 20%
overall lifetime risk.1,8
The complexity of organizing follow-up for HNC
patients includes the technical expertise required
(e.g., flexible naso-laryngoscopic examination, imaging
studies), the comorbidities experienced by the patients
and the psychofunctional disruptions caused by both
the disease and treatment.9 The main objectives of
follow-up in HNC is the evaluation of clinical response
and adverse effects of treatment, the early detection of
a recurrence or SPTs and the restoration of the patient
to their premorbid health status to the maximal extent
possible.2 In general, a HNC surveillance program must
consider several aspects: the index disease recurrence
rate, the optimal method for monitoring, and whether
earlier detection of recurrence has the potential to
result in successful salvage treatment and/or improved
survival.10
Two important factors that should be considered:
first, the influence of persistent tobacco and alcohol use
on the risk of SPTs in the aerodigestive tract, and second, the
differences between HPV-positive patients and negative
patients in terms of SPT incidence. For example, Leon et al11
carried out a matched case-control study in 514 patients with
HNC and found that the odds ratio of SPT for patients who
continued to smoke was 2.9 and for patients who continued
to use alcohol it was 5.2. With respect to HPV status, it has
been reported that patients withHPV-positive oropharyngeal
cancer have a lower risk of appearance of SPTs than HPV-
negative patients, particularly in those locations related to
tobacco use or alcohol consumption.12 Thus, Morris et al13
reviewed 75 087 patients with HNC and found that before
the 1990s, hypopharynx and oropharynx cancers carried the
highest risk of SPT, since then, during the HPV era, SPT risk
associated with oropharyngeal cancer has declined to the
lowest risk level of any subsite. A recent retrospective study
in a large cohort of HNC patients also showed that patients
with HPV-related tumors has a lower risk of development of
SPTs.14
This review aims at defining the average rate for SPTs
in HNC patient population and the pattern of synchro-
nous and metachronous tumors.
In order to evaluate the incidence of SPT on the long-
term follow-up of the HNC patients, we performed a
review of relevant articles on this issue.
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2 | PATIENTS AND METHODS
The Preferred Reporting Items for Systematic Review
and Meta-Analyses (PRISMA) method was used to con-
duct a systematic review of the current literature.15 The
search strategy aimed to include articles concerning the
development of SPTs in patients treated for HNC. A
PubMed internet search updated to April 1, 2019 was
performed for English language publications between
the years 1979 and 2019 using the following search
criteria in the title or abstract: “head and neck cancer,”
coupled with “second primary cancer” or “second pri-
mary tumor” or “second primary malignancy”,
“metachronous” and “synchronous.” The search results
were reviewed for potentially eligible studies. When
there was any information in the abstract about the
study addressing SPTs in HNC patients, the full text arti-
cle was searched. All review articles were also checked
in full. References from any full text articles were cross-
checked to ensure inclusion of all relevant publications
(Figure 1). Studies were selected if they met the follow-
ing inclusion criteria: (a) patients treated for HNC
(mucosal squamous cell carcinoma), (b) information on
the percentage of SPTs in these patients, and (c) on the
location of the SPTs is included in the text. Studies in
which the percentage of SPTs was analyzed in patients
with non-head and neck primary tumors, or when HNC
data were analyzed together with primaries from other
locations, were excluded. The same applied to articles in
which only a specific type of SPT was analyzed. This last
criterion was included because the objective of our study
was to assess the incidence of all possible SPTs and not
only in one location (e.g., lungs).
3 | RESULTS
Our search criteria identified, 5540 papers and after
removal of duplicates, 61 papers were selected for data
review and are summarized in Table 1.5,6,16-74 Most of
the studies were retrospective. Our review includes
456 130 patients from these 61 articles during a period
of 40 years (1979-2019). As can be seen in Table 1, data
on the percentage of synchronous and metachronous
tumors were not available in all articles, and some of
them only reported the total percentage of SPTs. The
mean rate of SPTs was 13.2% (95% CI: 11.56-14.84)). The
mean rate of synchronous SPTs was 5.3% (95% CI:
4.24-6.36). In the case of metachronous SPTs, with a
minimum follow-up of 22 months in the included studies
(range 22-252 months, median 55 months), the mean
rate was 9.4% (95% CI: 7.9-10.9). The large difference in
SPT rates observed in Table 1 could be explained by sev-
eral reasons: there is great variability between the stud-
ies, in terms of the location of tumors, the characteristics
of the patients, as well as the duration of follow-up
(since the incidence is cumulative, the duration of the
follow-up is critical and may explain much of the
observed difference) and the diagnostic methods used to
detect SPTs. In 24% of the studies panendoscopy was the
method used to screen for SPTs and in 15% some type of
imaging test, but in 61% of them there is no data about
FIGURE 1 Flow chart showing the
process of the study selection for the
systematic review
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TABLE 1 Compiled findings in selected series describing multiple primary tumors in the head and neck
Reference Year
Number
of patients Study % of ST % of MT % Total Location of SPT
Weichert and Schumrick16 1979 825 R 2.3 4.2 6,5 Head and neck, lung,
esophagus
Vrabec17 1979 1518 R 3.7 7.8 11.5 Head and neck, lung,
esophagus, other locations
Gluckman18 1979 162 P 9.2 NA NA Head and neck, lung
Weaver et al19 1979 124 P 12.9 NA NA Head and neck, lung,
esophagus
Shapshay et al20 1980 150 P 19 NA NA Head and neck, esophagus
Maisel and Vermeersch21 1981 449 R 8 4.7 12.7 Lung, esophagus
Atkinson et al22 1982 271 P 10.3 NA NA Head and neck, lung,
esophagus
Deviri et al23 1982 1660 R 0.9 4.2 5.1 Lung, digestive tract, bladder
McGuirt24 1982 100 P 18 NA NA Head and neck, lung,
esophagus
Black et al25 1983 645 P 8.9 NA NA Head and neck, lung and other
locations577 R 6.2 14.7 20.9
5337 R 5.1 8.7 13.8
Grossman et al26 1983 696 P 5.4 NA NA Head and neck, lung,
esophagus
Hordijk and de Jong27 1983 1148 R and P 2 15.5 17.5 Head and neck, lung and other
locations
Atkins et al28 1984 451 R 2.5 5 7.5 Head and neck, lung,
esophagus, other locations
Leipzig et al29 1985 384 P 8.9 NA NA Head and neck, lung,
esophagus
de Vries et al30 1986 210 R 1.9 15.7 17.6 Head and neck, lung,
esophagus, other locations
Lau et al31 1986 105 P 8.5 NA NA Head and neck, lung,
esophagus
Lundgren and Olofsson32 1986 295 R 1.4 11.2 12.6 Head and neck, lung,
esophagus
Schuller and Fritsch33 1986 53 P 11.3 NA NA Head and neck, lung
Shikhani et al34 1986 1961 R 4.9 4.7 9.6 Head and neck, esophagus
Shibuya et al35 1987 1429 R 2.3 7.2 9.5 Head and neck, digestive tract
Masaki et al36 1987 3162 R 1.2 7.1 8.3 Head and neck, digestive tract,
lung
Poppendieck37 1987 589 P 3.05 3.4 6.45 Head and neck. esophagus,
lung
Parker and Hill38 1988 208 P 7.2 NA NA Head and neck, lung
Poppendieck and Schrader39 1988 712 R 7.1 7.9 15 Head and neck. esophagus,
lung
Shaha et al40 1988 140 P 13 NA NA Head and neck. esophagus,
lung
Hordijk et al41 1989 141 P 1.4 NA NA Head and neck, lung
Panosetti et al42 1989 9089 R 3.9 5.3 9.2 Head and neck, Esophagus,
lung
(Continues)




of patients Study % of ST % of MT % Total Location of SPT
Panosetti et al43 1990 796 R 4.1 5.4 9.5 Head and neck, esophagus,
lung
Choy et al44 1992 573 P 1.9 0.5 2.4 Head and neck, esophagus,
lung
Esteller Moré et al45 1992 1212 R 3.13 NA NA Head and neck, esophagus,
lung
Schwartz et al46 1994 851 R 7.75 11.28 19.3 Head and neck, esophagus,
lung
Jones et al47 1995 3436 R 1 7 8 Head and neck, lung, other
locations
Dhooge et al48 1996 127 P 3.4 NA NA Head and neck, lung
León et al49 1999 1845 R 4.6 11.7 16.3 Head and neck, lung,
esophagus, other locations
Esposito et al50 2000 877 R 1.14 4.3 5.4 Head and neck, lung,
esophagus, other locations
Nikolaou et al51 2000 514 R 1.48 6.29 8.17 Head and neck, lung,
esophagus, other locations
Albright et al52 2001 23 150 364 < 40 y R NA NA 8.2 Head and neck, lung,
esophagus, other locations22 786 ≥ 40 y 21.3
Rafferty and O'Dwyer53 2001 425 R 2.1 6.4 8.5 Head and neck, esophagus,
lung
Stoeckli et al54 2001 358 R 6.4 9.8 16.2 Head and neck, esophagus,
lung
Spector et al55 2001 2550 R NA NA 8.9 Head and neck, lung,
esophagus, other locations
Holland et al56 2002 240 R 4.1 24.1 28 Head and neck, lung,
esophagus, other locations
Gao et al57 2003 20 074 R NA NA 17.6 Head and neck, esophagus,
lung, other locations
Warnakulasuriya et al58 2003 59 958 R NA NA 4.6 Head and neck, lung,
esophagus, other locations
Argiris et al5 2004 324 R NA NA 8 Head and neck, esophagus,
lung, other locations
Hujala et al59 2005 203 R 3.9 9.35 13.3 Head and neck, lung
Alvarez Marcos et al60 2006 633 R NA NA 11 Head and neck, lung,
esophagus
Sjögren et al61 2006 359 R 1.9 25.7 27.7 Head and neck, esophagus,
lung, other locations
Chuang et al62 2008 99 257 R NA NA 10.9 Head and neck, esophagus,
lung, other locations
Lopez Mollá et al63 2008 1330 R NA NA 7.73 Head and neck, lung,
esophagus, other locations
Rennemo et al64 2008 2063 P NA NA 17 Head and neck, lung, other
locations
Morris et al65 2011 75 087 R NA NA 23.2 Head and neck, lung,
esophagus, other locations
(Continues)
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which tests were used to diagnose SPTs. In several stud-
ies, a hospital or regional tumor registry was used for
the collection of the data, which explains the large pro-
portion of SPTs found outside the aerodigestive system,
with the consequent higher rate compared with studies
using panendoscopy alone. In order to extract more
information on the data available, we divided them in
different ways (Table 2). Studies were coded as prospec-
tive or retrospective, observing that the main bulk of
patients were included in retrospective studies. A lower
percentage of synchronous SPTs were observed in retro-
spective studies, 3.6%, compared with 8.5% in prospective
studies, but the overall percentage of SPTs was higher
for retrospective studies (13.4% vs 10.8%). The percentage
of synchronous SPTs was higher in prospective studies,
given that almost all studies in this group were con-
ducted during the first two decades of the present
review, that is, when the main diagnostic method used
for diagnosing SPTs was panendoscopy. In more recent
retrospective studies, other methods such as PET/CT
were used, which makes it easier to detected SPTs in dis-
tant locations during follow-up. When we divided the
studies by the time periods (1979-1998 vs 1999-2019), we
observed that most of them were published during the last
two decades and there was a difference in total percent-
ages of SPTs (11.1% vs 14.8%) between the two time
periods. The great difference in the number of patients is
most likely due to the ease with which large patient regis-





of patients Study % of ST % of MT % Total Location of SPT
Rodriguez-Bruno et al66 2011 64 R 6.25 NA NA Head and Neck
Jégu et al67 2013 6258 R NA NA 21.1 Head and neck, esophagus,
lung
Krishnatreya et al68 2013 4184 R 1.3 NA NA Head and neck, esophagus,
lung
Lee et al6 2013 937 R 7.2 11.4 18.6 Head and neck, esophagus,
lung, other locations
Tiwana et al69 2014 1658 R 3 24 27 Head and neck, lung,
esophagus, other locations
Patrucco and Aramendi70 2016 307 R 0.32 8.46 8.79 Head and neck, lung,
esophagus, other locations
Adeel and Siddiqi71 2018 221 R NA 8.14 NA Head and neck, esophagus,
lung
Adjei Boakye et al72 2018 109 512 R NA NA 12.3 Head and neck, lung,
esophagus, other locations
Leoncini et al73 2018 4005 R NA NA 8.6 Head and neck, lung, other
locations
Silén et al74 2019 151 R NA NA 26 Head and neck, lung,
esophagus, other locations
Abbreviations: MT, metachronous tumor; NA, not available; P, prospective; R, retrospective; SPT, second primary tumor; ST, synchronous tumor.
TABLE 2 Analysis of the significant differences in Table 1
Data Number of patients Mean % ST Mean % MT % Total Median follow-up (y)
By years 1979–1998 39 586 6 7.6 11.1 3.2
1999–2019 420 107 3.3 12.5 14.8 5
By type of study R 448 451 3.6 9.7 13.4 4.9
P 7679 8.5 6.5 10.8 2.6
Global 456 130 5.3 9.4 13.2 4.6
Abbreviations: MT, metachronous tumor; P, prospective; R, retrospective; ST, synchronous tumor.
COCA-PELAZ ET AL. 461
4 | DISCUSSION
It is known that HNC survivors have an increased mor-
bidity and mortality risk compared with the healthy pop-
ulation and this relates to treatment sequelae, coexisting
pulmonary, cardiac, and liver diseases as well as develop-
ment of SPTs secondary to smoking and alcohol use.75
SPTs that often arise from the aerodigestive epithelium,
are a major cause of mortality in HNC survivors.4 The
criteria defining a SPT were established by Warren and
Gates in 193276 as follows: (a) both tumors are malignant;
(b) the two cancers are anatomically separated by normal
mucosa; and (c) the possibility that one tumor represents
metastasis from the other is excluded. The index tumor is
the first diagnosed tumor, and the SPT is any malignancy
discovered thereafter. SPTs are classified as synchronous
if they are diagnosed at the same time as the index
tumor, for example, during staging of the index tumor, or
within 6 months after discovery of the index tumor. If the
SPT is discovered after a follow-up period of 6 months, it
is classified as metachronous.
It is remarkable that the great majority of the patients
in our review belong to retrospective studies from the last
20 years (more than 420 000 patients). Given this fact, it
is important to be aware of selection or other types of
bias. Chuang et al62 performed a study to assess the risk
of SPT and they calculated the standardized incidence
ratios (SIRs). The number of SPTs observed was com-
pared to the expected number of cancers to estimate the
SIRs. For all cancer sites combined, the SIR of SPTs was
1.86 and the 20-year cumulative risk was 36%. Lung can-
cer contributed the highest proportion of SPTs with a
20-year cumulative risk of 13%. They suggested that
patients with HNCs are at increased risk of developing a
SPT of the oral cavity and pharynx, esophagus, larynx
and lung. Using SIRs is the most appropriate method for
reporting the SPTs, but this methodology is used in only
a few studies.
The follow-up time for patients included in this
review is difficult to analyze as many studies do not pro-
vide data about the mean follow-up or only give a mini-
mum follow-up times that patients should have in order
to be included in the study. There were 20 articles given
data about median follow-up. The median follow-up time
is 4.6 years. However, as expected, for prospective studies
the duration was shorter (2.6 years). As mentioned, these
differences in follow-up periods could have influenced
the reported rates of SPTs, as the incidence is cumulative
between 3% and 7% per year.62
There are some articles in which the method used to
detect SPTs is panendoscopy (bronchoscopy, esophagoscopy,
direct laryngoscopy, and examination of the nasopharynx).
Hujala et al59 reviewed 203 consecutive patients with HNC
and reported a 3.9% rate of synchronous SPTs. During the
follow-up they found a 9.3% of metachronous SPTs.
However, other authors including Hordijk et al41 have
questioned the usefulness of this procedure given the
small number of tumors it detects (between 1% and 2%)
and conclude that “panendoscopy should therefore be
performed only as this diagnostic procedure is part of a
well-documented prospective study.” Dhooge et al48
analyzed the use of panendoscopy in patients treated
with HNC to evaluate the usefulness of each of their
procedures. They found a 3.4% rate of synchronous
SPTs. They conclude that rigid bronchoscopy should not
be performed if chest radiograph is normal. Also, they do
not recommend esophagoscopy as a screening procedure
in every HNC patients, and instead advocate direct oro-
hypopharyngo-laryngoscopy. Rodriguez-Bruno et al66
suggested that routine panendoscopy should not be per-
formed in nonsmoking patients since in their retrospective
study of 64 patients synchronous SPTs were found in 12.1%
of smoking patients and no synchronous SPTs were discov-
ered in nonsmoking patients. Priante et al77 analyzed the
efficacy of a single initial triple endoscopy in patients with
HNC. The diagnosis of SPTs was more frequent in the inter-
vention group than in a control group who underwent rou-
tine clinical examination. Although in the triple endoscopy
group 50% of the SPTs were diagnosed earlier, at the time of
initial evaluation, there was no impact on prognosis. These
conclusions should be taken with caution as the number of
patients is very limited. It is important to realize that many
studies report on a period with less advanced imaging tech-
niques through which SPTs were not detected by imaging,
but by panendoscopy. The importance and yield of pan-
endoscopy were probably higher in the past than now fol-
lowing contemporary imaging in the diagnostic work-up.
On the other hand, new endoscopic techniques, for exam-
ple, narrow band imaging (NBI),78 may detect SPTs earlier,
even as a synchronous instead of a metachronous tumor.
Studies with image-enhanced endoscopy have shown very
promising results in the detection of SPTs. Lugol's stain
isolates abnormal mucosal islands within otherwise normal
tissue, especially in the esophagus, enabling targeted biopsy.
When combined with NBI, it is reported to have a sensitivity
of 94.7% and a specificity of 90.4% to detect early stage
esophageal lesions.79 Bugter el al80 carried out a systematic
review on the diagnostic yield of Lugol chromoendoscopy
for esophageal SPTs in patients with HNC, showing that on
average, 15% of the patients with primary HNC that under-
went Lugol chromoendoscopy were diagnosed with an
esophageal-SPT, which compares favorably with the preva-
lence of retrospective nonscreening studies (1%-6%).
On the other hand, molecules such as DNAs, RNAs,
proteins, metabolites, and microbiota, could be found in
saliva. Therefore, salivary diagnostics has drawn significant
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attention for the detection of specific biomarkers of cancer.
Interestingly, salivary biomarkers signal not only for oral
and pharyngeal disorders but also for tumors in different
organs, suggesting that oral fluids may represent a substan-
tial reservoir of molecular and microbial information,
potentially useful to develop saliva-based biomarkers indic-
ative of both local and systemic diseases.81,82
The location of the index tumor is an important fac-
tor, but its impact remains difficult to analyze due to the
contradictory data found in the literature. Some authors
have shown that the index tumor site is related to the risk
of developing a SPT: Jones et al47 demonstrated that
patients with oral cavity and oropharyngeal cancer had a
significantly higher incidence of SPTs than patients with
laryngeal or hypopharyngeal index tumors, as well as
Haughey et al83 and Rafferty et al.53 Conversely, Patrucco
and Aramendi,70 and Hujala et al,59 showed that the larynx
is the location with the highest risk of developing a SPT.
Within larynx, the greatest risk for SPTs is connected with
supraglottic primary tumors, according to Leon et al.49 As
the annual rate of SPTs in most studies is constant (between
3% and 5%), the locations with the highest rate of cure will
be those with a higher cumulative incidence of SPTs.
Review of the data suggests that the most frequent
site of SPTs is the head and neck area, followed by the
lung and then, the esophagus. Rafferty et al53 showed
that the most common site, in their study of
425 patients, for the SPT was the oral cavity. They also
found a high incidence of SPTs in the lungs. Jones
et al47 found that the most common SPT site was the
lung for patients with oropharyngeal, hypopharyngeal,
and laryngeal index tumors. Schwartz et al46 discovered
that the esophagus was the most frequent location for
the synchronous SPT and the lung for the
metachronous SPT. Within the head and neck area, the
most frequent site for synchronous SPT was the pyri-
form sinus, and for the metachronous SPT the oral cav-
ity. Hordijk et al27 as well as Black et al,25 showed the
majority of the SPTs were found in the head and neck
region and lungs. Argiris et al5 found that the most fre-
quent site of SPTs was the lungs, esophagus, and less
frequently the head and neck.
Further, review of the literature reveals that SPTs is
associated with a decreased overall survival.5,47-49,51,53
SPTs may arise at unfavorable sites like lungs or esopha-
gus. Often, they arise in previously irradiated or operated
areas. Therefore, the choice of treatment of the SPT may
be influenced by the treatment of the index primary
tumor. Because of prior therapy, the full range of treat-
ment options may not be available (e.g., radiotherapy
dose). Moreover, general condition of the patient with a
newly diagnosed SPT can be severely compromised after
the first treatment which can also explain why these
tumors cannot always be treated according to accepted
guidelines.84,85
Argiris et al5 found that the causes of death in
324 HNC patients from their study, were: treated malig-
nant disease, treatment-associated acute or late complica-
tions, SPT, comorbidities (cardiac and respiratory illness)
and unknown causes. The cumulative incidence of SPT
was 5, 7, and 13% at 3, 5, and 10 years, respectively.
Accordingly, Rennemo et al64 reported that 351 (17.0%)
of 2063 patients with HNC developed SPTs, and the over-
all survival rates of these patients were 40.0% at 5 years
and 25.0% at 10 years, which were significantly lower
than those in the non-SPT group (P < .001), suggesting
the need for early identification and management of SPTs
to improve overall survival rates of these patients.
With this review we hope to raise awareness of the
problem of SPTs in patients with HNC. Many areas
remain understudied including the impact of HPV-related
disease and the association with SPTs, the association
between risk of SPTs and time from index primary tumor
treatment and the role of continued diagnostic imaging in
screening this high-risk population. By addressing these
factors, a more evidence-based approach to follow-up
strategies could be developed for patients with HNC.
5 | CONCLUSIONS
In this review, we found a mean rate of SPTs of 13.2% in
patients treated for HNC, with a great discrepancy
between studies. As SPTs significantly affect the progno-
sis of HNC patients, follow-up of HNC patients should
involve screening for SPTs. Since the head and neck area
and the lung are the sites more frequently involved,
follow-up should include a full head and neck examina-
tion including flexible laryngoscopy and consideration of
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